Insulet Q1 Net Income $91.1M, Adjusted EPS $1.42 Tops Estimates
PODD•Insulet reported Q1 net income of $91.1 million, or $1.30 per share, with adjusted earnings of $1.42 surpassing analysts’ $1.14 forecast. Revenue reached $761.7 million versus estimates of $728.2 million, prompting Insulet to raise its full-year revenue growth outlook on robust tubeless pump demand.
1. Q1 Financial Results
Insulet reported Q1 net income of $91.1 million, translating to $1.30 per share, and adjusted earnings of $1.42 per share, both exceeding forecasts by $0.16. Revenue climbed to $761.7 million, outpacing the $728.2 million consensus estimate and marking a year-over-year increase of over 14%.
2. Full-Year Guidance Raised
Following the quarterly beat, Insulet raised its annual revenue growth outlook, citing confidence in sustained demand trends. The updated guidance reflects expectations for continued expansion in its core tubeless insulin pump segment and improved contributions from new markets.
3. Drivers of Performance
Robust uptake of the Omnipod 5 system propelled both revenue and profitability, with strong subscription growth in the U.S. and accelerating adoption in Europe. Insulet also highlighted operational efficiencies and scale benefits that supported higher adjusted earnings margins.
